ASX-listed Telix Pharmaceuticals, a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical devices, has priced A$650m (US$427m) 2.375% convertible notes due July…
Australia: Telix Pharmaceuticals prices A$650m five-year convertible notes
…
…






